BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax (ABT-199) is an oral BCL-2 inhibitor that has currently received FDA approval for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia [19].